Bessa X, Elizalde J I, Boix L, Piñol V, Lacy A M, Saló J, Piqué J M, Castells A
Department of Gastroenterology, Institut de Malalties Digestives, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Catalonia, Spain.
Gastroenterology. 2001 Apr;120(5):1084-92. doi: 10.1053/gast.2001.23245.
Circulating tumor cells in peripheral blood may be detected using high-sensitivity molecular techniques in several types of solid neoplasms, but their significance in colorectal cancer is controversial. The aim of this study was to assess the prognostic value of carcinoembryonic antigen (CEA) messenger RNA (mRNA) detection in peripheral blood samples from patients with colorectal cancer.
Peripheral vein blood samples from 95 consecutive patients with histologically confirmed colorectal carcinoma were obtained immediately before surgery to determine the presence of circulating tumor cells by use of a reverse-transcription polymerase chain reaction targeting CEA mRNA. Endpoints of the study were disease-free and overall survival. Results are referred to the whole series and, more importantly, to the 68 patients who underwent surgery for cure.
After a median follow-up of 42 months, 19 of 68 patients (28%) operated on for cure had tumor relapse. In addition, 50 of 68 patients (73%) were alive. The probability of disease-free and overall survival was dependent on lymph node metastases and degree of differentiation, but not on the presence of circulating tumor cells (disease-free survival: relative risk, 1.00; 95% confidence interval [CI], 0.39-2.22, P = 0.99; overall survival: relative risk, 0.91, 95% CI, 0.34-2.43; P = 0.84). Similar results were obtained when all 95 patients with colorectal cancer were analyzed (disease-free survival: relative risk, 1.11; 95% CI, 0.63-1.95; P = 0.71; overall survival: relative risk, 1.21; 95% CI, 0.63-2.30, P = 0.55).
Preoperative detection of blood circulating tumor cells by means of reverse-transcription polymerase chain reaction of CEA does not have prognostic significance in patients with colorectal cancer.
利用高灵敏度分子技术可在多种实体瘤中检测外周血中的循环肿瘤细胞,但其在结直肠癌中的意义存在争议。本研究旨在评估检测结直肠癌患者外周血样本中癌胚抗原(CEA)信使核糖核酸(mRNA)的预后价值。
收集95例经组织学确诊为结直肠癌的连续患者术前外周静脉血样本,采用靶向CEA mRNA的逆转录聚合酶链反应确定循环肿瘤细胞的存在。研究终点为无病生存期和总生存期。结果针对整个队列进行分析,更重要的是,对68例行根治性手术的患者进行分析。
中位随访42个月后,68例行根治性手术的患者中有19例(28%)出现肿瘤复发。此外,68例患者中有50例(73%)存活。无病生存期和总生存期的概率取决于淋巴结转移和分化程度,而非循环肿瘤细胞的存在(无病生存期:相对风险,1.00;95%置信区间[CI],0.39 - 2.22,P = 0.99;总生存期:相对风险,0.91,95% CI,0.34 - 2.43;P = 0.84)。对全部95例结直肠癌患者进行分析时也得到了类似结果(无病生存期:相对风险,1.11;95% CI,0.63 - 1.95;P = 0.71;总生存期:相对风险,1.21;95% CI,0.63 - 2.30,P = 0.55)。
通过CEA的逆转录聚合酶链反应术前检测血液循环肿瘤细胞对结直肠癌患者无预后意义。